within the speedily evolving field of oncology investigation, accurate and economical mutation screening is important for establishing targeted therapies. The KRAS companies System performs a pivotal function Within this landscape by featuring complete options for KRAS mutation profiling and Assessment. KRAS mutations, present in about 95% of RAS-l